Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
DBGen Ocular Genomics | RCV001587382 | SCV001816084 | pathogenic | Achromatopsia 2 | 2021-06-04 | criteria provided, single submitter | clinical testing | |
Invitae | RCV002550194 | SCV003229228 | pathogenic | not provided | 2022-08-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the CNGA3 protein in which other variant(s) (p.Arg661Ser) have been determined to be pathogenic (PMID: 24676353, 30711023; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 1064470). This variant has not been reported in the literature in individuals affected with CNGA3-related conditions. This variant is present in population databases (rs745592705, gnomAD 0.0009%). This sequence change creates a premature translational stop signal (p.Asp507Ilefs*47) in the CNGA3 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 188 amino acid(s) of the CNGA3 protein. |
Molecular Genetics Laboratory, |
RCV001587382 | SCV001571302 | likely pathogenic | Achromatopsia 2 | 2021-04-15 | no assertion criteria provided | research |